{"nctId":"NCT02641561","briefTitle":"Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis","startDateStruct":{"date":"2014-10"},"conditions":["Post-ERCP Acute Pancreatitis"],"count":192,"armGroups":[{"label":"A (NS+Placebo)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Normal Saline","Drug: Placebo"]},{"label":"B (NS+IND)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Indomethacin","Drug: Normal Saline"]},{"label":"C (LR+Placebo)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lactated Ringer's Solution","Drug: Placebo"]},{"label":"D (LR+IND)","type":"EXPERIMENTAL","interventionNames":["Drug: Indomethacin","Drug: Lactated Ringer's Solution"]}],"interventions":[{"name":"Indomethacin","otherNames":["IND"]},{"name":"Lactated Ringer's Solution","otherNames":["LR"]},{"name":"Normal Saline","otherNames":["NS"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1 Subjects who are undergoing endoscopic retrograde cholangiopancreatography (ERCP)\n\n* Age \\> 18 years\n* Non-pregnant\n* Non-prisoners\n* Subjects who can sign informed consent\n* Serum Creatinine \\< 1.2 milligrams/deciliter (mg/dL)\n* Subjects without renal failure (acute or chronic)\n* Subjects without congestive heart failure (ejection fraction \\< 40%)\n* Subjects without cirrhosis of the liver\n* Subjects without allergy to aspirin or non-steroidal anti-inflammatory drugs (NSAIDS)\n* Subjects not on non-steroidal anti-inflammatory drugs NSAIDS prior to enrollment\n\nExclusion Criteria:\n\n* Subjects who are not undergoing ERCP\n* Age \\< 18 years\n* Pregnancy\n* Prisoners\n* Subjects lacking the capacity to consent for themselves\n* Serum Creatinine \\> 1.2 milligrams/deciliter (mg/dL)\n* Subjects with renal failure (acute and chronic)\n* Subjects with congestive heart failure (ejection fraction \\< 40%)\n* Subjects with cirrhosis of the liver\n* Subjects with allergy to aspirin or non-steroidal anti-inflammatory drugs (NSAIDS)\n* Subjects with gastrointestinal hemorrhage\n* Subjects on chronic non-steroidal anti-inflammatory drugs NSAIDS\n* Subjects with acute pancreatitis the day of their procedure (CITE 1-3)(APPENDIX 1)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Either Elevated Amylase or Lipase 3 x Upper Limit of Normal","description":"amylase or lipase","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Imaging Suggestive of Acute Pancreatitis","description":"Imaging may include Computer Tomography","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Acute Respiratory Distress Syndrome (ARDS) After ERCP as Assessed by ARDSnet Criterion (Below)","description":"bilateral opacities on chest imaging not explained by other lung pathology, respiratory failure not explained by heart failure or volume, and overload and a pulmonary arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio under 300, PaO2/FiO2 ratio is the partial pressure arterial oxygen and fraction of inspired oxygen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)","description":"Heart rate \\> 90 beats per minutes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)","description":"Respiratory rate \\> 20 breaths per minute","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)","description":"PaCO2 \\< 4.3 kilopascal (kPa) (32 mmHg)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)","description":"Temperature \\< 36°C(96.8°F) or \\> 38°C(100.4°F)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)","description":"white blood cell (WBC) count \\< 4000 cells/mm³ (4 x 109 cells/L)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)","description":"\\> 10% immature neutrophils (band forms).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Sepsis After ERCP as Assessed by Infectious Source Defined by Positive Microbiology Culture","description":"positive blood culture","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Multiple Organ Failure (MOF) After ERCP as Assessed by Elevated Creatinine Blood Test","description":"creatinine \\> 1.5 milligrams/deciliter (mg/dL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Multiple Organ Failure (MOF) After ERCP as Assessed by Elevated International Normalized Ratio (INR)","description":"INR \\> 1.5","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Pancreatic Pseudocyst After ERCP as Assessed by Abdominal Imaging Suggestive of Pseudocyst","description":"Imaging may include Computer Tomography","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Pancreatic Abscess After ERCP as Assessed by Abdominal Imaging Suggestive of Pancreatic Abscess","description":"Imaging may include Computer Tomography","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Perforation After ERCP as Assessed by Abdominal Imaging Suggestive of Perforation","description":"Imaging may include Computer Tomography","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Who Undergo Surgery After ERCP, as Assessed by Surgical Operative Report","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Mortality After ERCP as Assessed by Medical Record Reporting","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Post-procedural Medical Care (ED Visit, Urgent Care, Hospitalization) as Assessed by Medical Record and Patients Self-reporting","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Length of Stay (LOS) of Participants After ERCP if Medical Care is Sought as Assessed in Days","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"3.5"},{"groupId":"OG001","value":"2.2","spread":"4.1"},{"groupId":"OG002","value":"1.9","spread":"3.4"},{"groupId":"OG003","value":"4.3","spread":"8.4"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Who Were Readmitted After ERCP as Assessed by Medical Record and Patients Self-reporting","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":48},"commonTop":["Acute Renal Failure","Pulmonary Edema","Splenic Laceration"]}}}